ArticleCureus2025
Adjuvant Chemotherapy in Children With Enucleated Retinoblastoma and Histopathologic High-Risk Features: Survival Outcomes From a Single Institution in a Middle-Income Country.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRetinoblastoma is the most common intraocular malignancy in children. Although primary enucleation continues to be a standard treatment for advanced disease, specific histopathologic high-risk features substantially increase the likelihood of extraocular dissemination. Adjuvant chemotherapy aims to reduce this risk; however, evidence from middle-income countries remains limited.
objectiveTo determine the prevalence of histopathologic high-risk features in enucleated retinoblastoma and to assess relapse risk and event-free survival (EFS) among patients treated with adjuvant chemotherapy.
methodsWe conducted a retrospective analytical study of children with unilateral retinoblastoma treated with primary enucleation and of those with bilateral disease in whom the more affected eye was enucleated before any therapy, between January 2008 and December 2018. Patients presenting high-risk histopathologic features received adjuvant chemotherapy with vincristine, etoposide, and carboplatin (VEC). EFS was estimated using the Kaplan-Meier method and compared using the log-rank test.
resultsA total of 101 patients were included; 74 (73%) had unilateral disease. The mean age at diagnosis was 2.1 years. Most eyes demonstrated advanced intraocular involvement (International Classification of Intraocular Retinoblastoma (ICRB) Group E: 82, 81.2%; Group D: 13, 12.9%). Histopathologic high-risk features were common: choroidal invasion occurred in 42 (41.6%) (17, 40.4% massive ≥3 mm), postlaminar optic nerve invasion in 11 (26.2%), and positive optic nerve margin in 16 (38%). Scleral invasion was identified in 20 (21.5%), and anterior chamber invasion in 14 (14%). Thirteen patients (13%) relapsed, all with fatal outcomes. Ten-year EFS was 83.3%. Massive choroidal invasion, scleral invasion, and postlaminar optic nerve invasion were the strongest predictors of poor outcome, and their coexistence was associated with the highest relapse risk.
conclusionsHistopathologic high-risk features are common among children undergoing enucleation for advanced retinoblastoma. Adjuvant chemotherapy is warranted in cases with massive choroidal invasion, scleral infiltration, or postlaminar optic nerve involvement, given their strong association with metastatic relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.